Skip to content

Phase 1b trial reports promising outcomes with olverembatinib plus blinatumomab in relapsed or refractory CML or ALL
SOHO 2026 posters not to miss: MPN edition with Dr. Gabriela Hobbs
Young investigators define the SOHO difference
Dr. Jerald Radich highlights meaningful posters in CML at SOHO 2026
The state of SOHO: a year of growth and opportunity

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Cellular Therapy

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Leukemia

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Lymphoma

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Multiple Myeloma

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Myelodysplastic Syndromes

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

September 20, 2026

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Leukemia Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Elias Jabbour

Section Editor of ALL

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center

ASH 2025 Leukemia Acute Lymphoblastic Leukemia News Video Interviews

Drs. Zheng and Bona discuss financial toxicity in pediatric ALL

by SOHO Insider Editors
March 15, 2026
0 Comments

Cellular Therapy Leukemia Acute Lymphoblastic Leukemia News

Fractionated var-cel induces deep remissions, has low incidence of CRS in patients with B-ALL

by Kerri Fitzgerald
March 13, 2026
0 Comments

SOHO UK Leukemia Acute Lymphoblastic Leukemia Multiple Myeloma Myelodysplastic Syndromes News Video Interviews

Dr. Jessica Manson discusses multidisciplinary HLH management at SOHO UK

by SOHO Insider Editors
March 11, 2026
0 Comments

Cellular Therapy Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Multiple Myeloma Myelodysplastic Syndromes News

Why clinicians should lead hospitals, according to Prof. Amanda Goodall

by Leah Sherwood
March 10, 2026
0 Comments

SOHO UK Cellular Therapy Acute Lymphoblastic Leukemia Aggressive B-Cell Lymphomas

A view from SOHO UK: navigating the challenges and complexity of haematology

by SOHO Insider Editors
March 2, 2026
0 Comments

DIDACT group photo 3

SOHO UK Leukemia Acute Lymphoblastic Leukemia Lymphoma Aggressive B-Cell Lymphomas

DIDACT’s mission to train and mentor the next generation of UK blood cancer triallists

by Leah Sherwood
March 2, 2026
0 Comments

SOHO UK skyline

SOHO UK Leukemia Acute Lymphoblastic Leukemia News Society Updates

SOHO UK mirrors traditional SOHO meeting with UK twist

by Leah Sherwood
March 1, 2026
0 Comments

Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia News

Assay targeting KMT2A rearrangements in AML now available

by SOHO Insider Editors
February 16, 2026
0 Comments

SOHO 2026 Leukemia Acute Lymphoblastic Leukemia News SOHO Insider Podcast Society Updates

Public-private partnerships needed to sustain progress in blood cancer treatment

by SOHO Insider Editors
February 9, 2026
0 Comments

Update

Leukemia Acute Lymphoblastic Leukemia Lymphoma T-Cell Lymphoma News

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

by SOHO Insider Editors
February 4, 2026
0 Comments

1
2
3
4
5

Top Categories

Cellular Therapy

82

Leukemia

134

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Cellular Therapy

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Leukemia

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Lymphoma

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Multiple Myeloma

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Myelodysplastic Syndromes

FDA approves larger Nelarabine vial size for T-ALL and T-LBL

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Phase 1b trial reports promising outcomes with olverembatinib plus blinatumomab in relapsed or refractory CML or ALL

SOHO 2026 posters not to miss: MPN edition with Dr. Gabriela Hobbs

POWERFUL-400x400

Young investigators define the SOHO difference

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.